

DAFTAR PUSTAKA

1. Bruns J, Hauser WA. The epidemiology of traumatic brain injury: a review Epilepsia 2003; 44(S10):2-10
2. Winkler EA. et al. Cerebral Edema in Traumatic brain injury. Neurosurgery Clinics of North America. Elsevier Inc 2016; 27(4): pp. 473–88. doi: 10.1016/j.nec.2016.05.008
3. Vos PE. Arrastia RD. Traumatic brain injury. 1st ed. Oxford: Wiley Blackwell; 2015. pp. 3.
4. Evans RW. Neurology and trauma (2nded). New York:Oxford, 2006.
5. Khan A, Prince M, Brayne C, Prina AM. Lifetime prevalence and factors associated with head injury among older people in lowand middle income countries: a 10/66 study. PLoS One 10 2015:e0132229.
6. Sekeon SAS, Maja PS, Kembuan M. Executive function disorder in acute traumatic brain injuryin Manado, Indonesia. Global Journal of Medicine and Public Health 2015; 4(2). ISSN 2277-9604
7. Zeng J. et al. Emodin attenuates brain edema after traumatic brain injuryin rats, 2017;10(11):15213–20.
8. Michinaga S. and Koyama Y. Pathogenesis of brain edema and investigation into anti- dema drugs, International Journal of Molecular Sciences 2015;16(5): 9949–75. doi: 10.3390/ijms16059949.

9. Donkin JJ. and Vink R. Mechanisms of cerebral edema in traumatic brain injury: Therapeutic developments, Current Opinion in Neurology 2010;23(3):293–9.doi:10.1097/WCO.0b013e328337f451.
10. Alluri H, Wilson RL, Anasooya Shaji C, Wiggins-Dohlvik K, Patel S, Liu Y, Peng X, Beeram MR, Davis ML, Huang JH and Tharakan B. Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition. PLoS One 2016; 11: e01544
11. Saekhu M, et all. MMP-9, Brain edema, and length of hospital stay of patients with spontaneous supratentorial intracerebral hemorrhage after hematoma evacuation along with the administration of tigecycline. Med J Indones, December 2016: 25(4): 221-6. eISSN: 2252-8083
12. Jia F, Pan Y, Mao Q, Liang Y, Jiang J. Matrix metalloproteinase-9 expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. Journal of Neurotrauma. June 2010. 27:1059–68.DOI: 10.1089/neu.2009.1067
13. Hayashia T. Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats. Elsevier Brain research. 2009;172-7. doi:10.1016/j.brainres.2009.05.040
14. Haddas O, et al. Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. PLoS ONE 8(10): e76904.doi:10.1371/journal.pone.0076904

15. Prasetyo E, Islam AA, Hatta M, Widodo D, Pattelongi I. The Profile of MMP-9, MMP-9 mRNA Expression, -1562 C/T polymorphism and outcome in high-risk traumatic brain injury: the effect of therapeutic mild hypothermia. *Neurologia medico-chirurgica Advance*. October 2017.doi: 10.2176/nmc.oa.2016-0322
16. Moore AJ. Management of severe head injury. In: Newell DW, editor. *Neurosurgery*. London: Springer-Verlag; 2005. pp. 369-71. ISBN 1-85233-522-X
17. Webster KM. et al. Inflammation in epileptogenesis after traumatic brain injury. *Journal of Neuroinflammation* 2017; 14(1): pp. 1–17. doi: 10.1186/s12974-016-0786-1.
18. Zollman, Felise S. Manual of traumatic brain injury: assessment and management. 2nd ed. New York, NY : Demos Medical Publishing; 2016. pp. 369-71. ISBN 9781620700938
19. McBride DW. et al. Reduction of cerebral edema after traumatic brain injury using an osmotic transport device. *Journal of Neurotrauma* 2014; 31(23): 1948–54. doi: 10.1089/neu.2014.3439.
20. Bosoi CR, Rose CF. Brain edema in acute liver failure and chronic liver disease: Similarities and differences. *Neurochem. Int* 2013; 62: 446–57.
21. Wright G, Sharifi Y, Jover-Cobos, M. Jalan, R. The brain in acute on chronic liver failure. *Metab. Brain Dis* 2014; 4: 965–73.

22. Kahle KT, Simard JM, Staley KJ, Nahed BV, Jones PS, Sun D. Molecular mechanisms of ischemic cerebral edema: Role of electroneutral ion transport. *Physiology (Bethesda)* 2009; 24: 257–65.
23. Rabinstein AA. Treatment of brain edema in acute liver failure. *Curr. Treat. Opt. Neurol* 2010; 2: 129–41.
24. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. *Biochim. Biophys. Acta* 2009; 4: 842–57.
25. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proc. Natl. Acad. Sci. USA* 2009; 6: 977–82.
26. Jha, RM., Kochanek, PM., Simard, JM., Pathophysiology and treatment of cerebral edema in traumatic brain injury. *Neuropharmacology* 2019; 145: 230–46
27. Aliah A, Widjaja D. Edema Cerebri, pendekatan patogenetik dan terapeutik. Makassar: Laboratorium Saraf FK UH 2006:1-19
28. Grossetete M. et al. 'Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury', *Neurosurgery* 2009; 65(4):702-8. doi: 10.1227/01.neu.0000351768.11363.48.
29. Falo MC, Fillmore HL, Reeves TM, Phillips LL. Matrix metalloproteinase-3 expression profile differentiates adaptive and


- maladaptive synaptic plasticity induced by traumatic brain injury. *J. Neurosci. Res* 2006; 84: 768–81.
30. Gidday JM. et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. *American Journal of Physiology-Heart and Circulatory Physiology* 2005; 289(2): H558–68. doi: 10.1152/ajpheart.01275.2004.
31. Vajtr D. et al. Correlation of ultrastructural changes of endothelial cells and astrocytes occurring during blood brain barrier damage after TBI with biochemical markers of blood brain barrier leakage and inflammatory response. *Physiological Research* 2009; 58(2): pp. 263–8.
32. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. *Nat Rev Neurosci* 2005; 6:931–44.
33. Wang L, Zhang ZG, Zhang RL, Gregg SR, Hozeska-Solgot A, LeTourneau Y, Wang Y, Chopp M. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. *J Neurosci* 2009; 26:5996–6003.
34. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. *Glia* 2005; 50:329–39.
35. Liu KJ, Rosenberg GA. Matrix metalloproteinases and free radicals in cerebral ischemia. *Free Radic Biol Med* 2005; 39: 71–80.

36. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. *Glia* 2002; 39: 279–91.
37. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. *J Cereb Blood Flow Metab* 2007; 27:697–709.
38. Rosenberg GA, Taheri S, Jalil EC. Brain Edema in Neurological Diseases; Neurochemical Mechanisms in Disease, Neurobiology. London. Springer ScienceBusiness Media. 2011: pp.125-56. doi: 10.1007/978-1-4419-7104-3.
39. Yang Z, Fan R, Sun P, Cui H, Peng W. Rhubarb attenuates cerebral edema via inhibition of the extracellular signal-regulated kinase pathway following traumatic brain injury in rats. *Phcog Mag* 2018;14:134-9.
40. Ding JY, Kreipke CW, Schafer P, Schafer S, Speirs SL. Synapse Loss Regulated by Matrix Metalloproteinases in Traumatic brain injury Is Associated with Hypoxia-Inducible Factor-1 α Expression. *Brain Res* 2009; May 1; 1268: 125–34.
41. Leung LY, et al. Blast related neurotrauma: a review of cellular injury. *Mol Cell Biomech.* 2008; 5:155–168. [PubMed: 18751525]


42. Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. *J Neurosci Methods*. 1991; 39:253–262. [PubMed: 1787745]
43. Guilfoyle MR, Carpenter KL, Helmy A, Pickard JD, Menon DK, Hutchinson PJ. Matrix metalloproteinase expression in contusional traumatic brain injury: A paired microdialysis study. *J Neurotrauma*. 2015;32(20):1553-1559.doi:10.1089/neu.2014.3764
44. Copin, JC., Rebetez, M.M.L., Turck, N. et al. Matrix metalloproteinase 9 and cellular fibronectin plasma concentrations are predictors of the composite endpoint of length of stay and death in the intensive care unit after severe traumatic brain injury. *Scand J Trauma Resusc Emerg Med* 20, 83 (2012). <https://doi.org/10.1186/1757-7241-20-83>.
45. Grosssetete M, Phelps J, Arko L, Yonas H, Rosenberg GA. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. *Neurosurgery* 2009;65: 702–708.
46. Zheng K, Li C, Shan X, Liu H, Fan W, Wang Z, Zheng P. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with moderate and severe traumatic brain injury. *Neurol India* 2013;61:606–609.

DAFTAR LAMPIRAN




LAMPIRAN 1. SURAT KEPUTUSAN PEMBIMBING MAKALAH AKHIR



LAMPIRAN 2. SURAT KEPUTUSAN PENGUJI MAKALAH AKHIR



LAMPIRAN 3. SURAT ETHICAL CLEARANCE

 <p>KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN KESEHATAN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, M.Med.,Ph.D, Sp.GK, TELP. 081241850859, 0411 5780103, Fax : 0411-581431</p> 			
<u>REKOMENDASI PERSETUJUAN ETIK</u> Nomor : 785/UN4.6.4.5.31/ PP36/ 2020 Tanggal: 1 Desember 2020			
Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :			
No Protokol	UH20110634	No Sponsor Protokol	
Peneliti Utama	dr. Rendra Budi Dharma	Sponsor	
Judul Peneliti	Menjulur Kadar MMP-9 (Matrix Metalloproteinase - 9) pada Tikus Jantan Balur Wistar yang Mengalami Edema Cerebri Post Cedera Otak Traumatika		
No Versi Protokol	1	Tanggal Versi	6 November 2020
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium Hewan Fakultas Kedokteran Universitas Hasanuddin Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 1 Desember 2020 sampai 1 Desember 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		
Kewajiban Peneliti Utama: <ul style="list-style-type: none"> • Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan • Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan • Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah • Menyerahkan laporan akhir setelah Penelitian berakhir • Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation) • Mematuhi semua peraturan yang ditentukan 			